Atlas Trials

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

Clinical trial NCT03952325 · TERMINATED

Trial details

NCT number
NCT03952325
Sponsor
Odonate Therapeutics, Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2019-07-09
Primary completion
2021-06-23
Enrollment
294

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.